GRI Bio Stock (NASDAQ:GRI)
Previous Close
$0.77
52W Range
$0.30 - $65.00
50D Avg
$0.76
200D Avg
$2.87
Market Cap
$6.61M
Avg Vol (3M)
$4.50M
Beta
-1.80
Div Yield
-
GRI Company Profile
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CUE | Cue Biopharma, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| GBIO | Generation Bio Co. |
| CNTB | Connect Biopharma Holdings Limited |
| IKNA | Ikena Oncology, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| EWTX | Edgewise Therapeutics, Inc. |
| HCWB | HCW Biologics Inc. |
| CCCC | C4 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| XLO | Xilio Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| STTK | Shattuck Labs, Inc. |
| PASG | Passage Bio, Inc. |
| CELC | Celcuity Inc. |